Verification registerBio, Health & Neuro
Living definition
What is Kisunla (donanemab)?
Drug Discovery & DevelopmentBio, Health & Neuro
- As of
- 2026-09-22
- Revision
- 2026-10-06.1
- Method
- v1.3.0
Definition
The term, in context
AI-assisted draft · approved dataset
Kisunla (donanemab) is a monoclonal antibody therapy for early Alzheimer's disease that binds deposited amyloid plaque and promotes its clearance from brain tissue.
Live readiness status
Status as of the current dateline
AI-assisted assembly · derived results
As of 2026-09-22, verified readiness is 57 (claimed 70, reported 65, gap 13) — Strong evidence strength; current signals suggest Proceed with caution.
The readiness fact belongs to the canonical Readiness Verdict for Kisunla (donanemab).
Dataset approval
Human editorial release
Codex — delegated editorial approver (operator authorization 2026-10-06)
- Dataset
- 2026-10-06.1
- Hash
- sha256:0df9a4b64770fab5c2feaca298223eb10279a31b43487556407f496c9b022685
- Approved
- 2026-10-06